XML 83 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration Agreements (Other Collaborations) (Details) - USD ($)
1 Months Ended 12 Months Ended 36 Months Ended
Oct. 31, 2008
Dec. 29, 2017
Dec. 30, 2016
Jan. 01, 2016
Dec. 29, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Maximum potential milestone payments   $ 1,900,000,000     $ 1,900,000,000
Percentage of maximum potential milestone payments - clinical development   9.00%     9.00%
Percentage of maximum potential milestone payments - regulatory   49.00%     49.00%
Percentage of maximum potential milestone payments - commercial   42.00%     42.00%
GlaxoSmithKline [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Percent of royalty on net sales 3.00%        
Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Percentage of costs   33.33%      
Daiichi Sankyo [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Maximum amount eligible for development and regulatory milestones   $ 130,000,000     $ 130,000,000
Revenue recognized, milestones   0 $ 15,000,000 $ 0  
Merck [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Maximum amount eligible for development and regulatory milestones   231,000,000     231,000,000
Revenue recognized, milestones   0 5,000,000 3,000,000  
Maximum amount eligible for royalties on sales under collaborations agreement   375,000,000     375,000,000
Collaborative Arrangement with BMS [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Maximum amount eligible for development and regulatory milestones   240,000,000     240,000,000
Revenue recognized, milestones   12,500,000 0 0  
Maximum amount eligible for royalties on sales under collaborations agreement   150,000,000     150,000,000
Sanofi [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Maximum amount eligible for development and regulatory milestones   $ 745,000,000.0     745,000,000.0
Revenue recognized, milestones     $ 0 $ 0 $ 0
Bristol Myers Squibb [Member] | Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Percentage of costs   66.67%